Neurological complications are reported in approximately 4% of people with severe COVID-19. New data reveal that treatment with dexamethasone or remdesivir during acute COVID-19 is associated with a reduced frequency of neurological complications, including stroke, seizures and meningitis. Importantly, the drugs showed a synergistic effect when used together. Moreover, dexamethasone treatment was associated with a decreased risk of neurological complications in individuals with non-hypoxic COVID-19.
References
Original article
Grundmann, A. et al. Fewer COVID-19 neurological complications with dexamethasone and remdesivir. Ann. Neurol. https://doi.org/10.1002/ana.26536 (2022)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kiani, L. Preventing COVID-19 neurological complications. Nat Rev Neurol 18, 699 (2022). https://doi.org/10.1038/s41582-022-00744-4
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41582-022-00744-4